Today
Labor urged to back science, boost spending on research
Medical technology chiefs want Labor to prioritise science in its second term and stop a slide in Australia’s research and development funding.
Barrenjoey, Morgans test IPO appetite for $100m-plus Tetratherix
In the lead-up to the IPO, Tetratherix has tapped Emma Cleary – a former CFO of Navis Capital’s $1.5 billion Device Technologies – to chair its board.
Yesterday
Business calls for productivity push, more gas in Labor’s second term
Australia’s top CEOs want Anthony Albanese to reform the tax system, fix productivity and give them a seat at the policy table in his second term.
This Month
The Aussie bringing Black Mirror-esque brain tech to reality
This neurologist has built technology allowing humans to control machines with just their thoughts. Now he’s racing Tesla’s founder to take it to the masses.
Biotech Dimerix lands $940m licensing deal for kidney drug sales
The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.
How Labor weaponised Medicare (again) to take on Peter Dutton
Labor has put health at the centre of the election campaign in a strategy to demonise the opposition leader and woo voters with the promise of free doctor visits.
April
Pharmacy Guild coming to you from the Chairman’s Lounge
Labor has been remarkably kind to the chemists’ lobby group recently, but we suspect that’s more due to their choice of lobbyist than airline lounge access.
Diagnostics company BlinkLab seeks funds ahead of FDA submission
Street Talk understands the ASX-listed company’s stockbrokers Alpine Capital and Westar Capital will launch a $5 million single-tranche placement on Tuesday morning.
Telix setback in drug approval in US, amid Trump workforce cuts to FDA
Telix CEO Christian Behrenbruch hinted changes to the US Food and Drug Administration have hampered approval of its new brain cancer imaging agent.
Billion-dollar medical start-ups say Trump could force a US move
Nanosonics chief executive Michael Kavanagh says the government should step in and help domestic development, a sentiment echoed by ResMed boss Mick Farrell.
‘Tariff-exempt’ ResMed boosts US manufacturing
Chief executive Mick Farrell says he’s confident the medical device company’s exports from Australia and Singapore will not be subject to Donald Trump’s levies.
GP salaries of $400k-plus put in spotlight by healthcare election
Labor says GPs will be paid more if they bulk-bill patients, but doctors are doubtful as the costs of running a clinic rise.
This $1.3b biotech is still run out of a spare bedroom in Melbourne
It’s been a volatile few years for Neuren, the neurological disorder treatment group which has seen shares rocket, then slump. Now it has a promising new drug.
Cochlear-backed Epiminder targets 2025 IPO as FDA authorisation lands
E&P Capital, which helped Epiminder raise funds this year, will lead the bookbuild alongside Morgans.
GP earnings to top $400k a year under bulk-billing plan: Butler
Labor says GPs will earn $124,000 a year more than they did three years ago, once its bulk-billing incentives are implemented.
Contradictions at every turn in the NSW government’s Healthscope war
The state has outlawed private hospitals running acute wards – and the private hospital giant wants to hand over its facility. But no deal is imminent.
Eli Lilly issues warning for Australia as Trump signals pharma tariffs
In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.
Monash IVF disaster shows board’s market insensitivity
Giving a client the wrong embryo and not realising until well after the child is born seems like it should be a big deal to the board.
Measles outbreak linked to Tim Gurner’s anti-ageing spa
The property developer’s Saint Haven is an ‘active public exposure site’ of a measles case.
How this $115b ASX giant plans to win from both sides of the trade war
On the front line of the tit-for-tat tariff fight between the US and China, Australian companies are trying to find a way to play both sides.
‘Could be next Cochlear or ResMed’: heart device maker wins FDA approval
EBR Systems, backed by investors such as HESTA, Hostplus and private equity veteran Mark Carnegie, can start selling its technology within months.
Botanix Pharmaceuticals taps investors for $40m; Euroz, E&P in tow
The ASX-listed company had Euroz Hartleys and E&P Capital offering shares at 33¢ each.
Ramsay Health Care doesn’t want to waste a Healthscope crisis
The ASX-listed hospitals group is trying to fly below the radar with Healthscope, but the door is ajar. There is blood in the water and sharks come in all varieties.
NSW says Northern Beaches deal depends on Healthscope sale process
The government said it needed to know who was in charge at the private hospital giant, which is currently owned by Brookfield Asset Management but up for sale.
Oaktree Capital kicks off debt process for GenesisCare
It is understood McKnight will seek to refinance the so-called “take-back debt”, a facility that was arranged and funded by the Oaktree-led consortium of financiers.